<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00816205</url>
  </required_header>
  <id_info>
    <org_study_id>RDD102</org_study_id>
    <nct_id>NCT00816205</nct_id>
  </id_info>
  <brief_title>An Open Label Study to Examine the Effect of Coated Nifedipine Suppositories on Anal Pressure in Healthy Subjects</brief_title>
  <official_title>An Open Label Study to Examine the Effect of Coated Nifedipine Suppositories on Anal Pressure in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RDD Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RDD Pharma Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, dose-finding study. Approximately 8 healthy subjects will be&#xD;
      participating in this study.&#xD;
&#xD;
      Within one week after the screening visit, subjects who meet all inclusion criteria and none&#xD;
      of the exclusion criteria will enter a one day treatment period. During this period, 4 anal&#xD;
      manometric studies will take place. Study medication (Coated Nifedipine suppositories at&#xD;
      various doses) will be administered at pre-determined intervals. During the study, blood&#xD;
      samples will be obtained for plasma Nifedipine analysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After detrminig baseline resting anal pressure with a manometric test, coated Suppositories&#xD;
      will be administered intra rectally. Subjects will take rectally a total of 3 Coated&#xD;
      Suppositories per study. 90 minutes after each coated suppository insertion this suppository&#xD;
      will be removed and a amnometric study will be performed:&#xD;
&#xD;
      The first dose will contain 4 mg of Nifedipine and the manomentric measurement performed&#xD;
      afterwards will be used to determine baseline anal pressures.&#xD;
&#xD;
      The second dose will contain 12 mg of Nifedipine. The third dose will contain 24 mg of&#xD;
      Nifedipine. The primary efficacy parameter is change in Resting Anal Pressure from baseline.&#xD;
&#xD;
      The secondary efficacy parameters include the following:&#xD;
&#xD;
        -  The ratio of change in anal pressure to plasma Nifedipine level.&#xD;
&#xD;
        -  The ratio of change in anal pressure to change in blood pressure.&#xD;
&#xD;
        -  The ratio of change in anal pressure to change in heart rate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">April 2009</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy parameter is change in Resting Anal Pressure from baseline.</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <condition>Anal Resting Pressure</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is an open label, dose-finding study. After detrminig baseline resting anal pressure with a manometric test, coated Suppositories will be administered intra rectally. Subjects will take rectally a total of 3 Coated Suppositories per study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coated Nifedipine Suppositories</intervention_name>
    <description>Subjects will take rectally a total of 3 Coated Suppositories per study. 90 minutes after each coated suppository insertion this suppository will be removed and a amnometric study will be performed:&#xD;
The first dose will contain 4 mg of Nifedipine and the manomentric measurement performed afterwards will be used to determine baseline anal pressures.&#xD;
The second dose will contain 12 mg of Nifedipine. The third dose will contain 24 mg of Nifedipine.</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects meeting the following criteria will be eligible to participate in the trial:&#xD;
&#xD;
          -  Signed written informed consent;&#xD;
&#xD;
          -  Male or female subjects 18 to 55 years of age;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects are excluded from participation in the study if any of the following criteria&#xD;
        apply:&#xD;
&#xD;
        Has a clinically significant history or presence of any of the following conditions:&#xD;
&#xD;
          -  Known allergy to Nifedipine, polyethylene-glycol, Propylene-glycol or silicone.&#xD;
&#xD;
          -  Active or past history of disease that requires medication or clinical follow up.&#xD;
&#xD;
          -  Malignant disease within 5 years of screening;&#xD;
&#xD;
          -  History of ano rectal disease.&#xD;
&#xD;
          -  History of gastrointestinal disease.&#xD;
&#xD;
          -  History of gastrointestinal bleeding.&#xD;
&#xD;
          -  History of rectal surgery.&#xD;
&#xD;
          -  History of gastrointestinal surgery.&#xD;
&#xD;
          -  History of HIV.&#xD;
&#xD;
          -  In need of chronic use of medication, with the exception of birth control medications.&#xD;
&#xD;
          -  Currently uses medication for acute illness.&#xD;
&#xD;
          -  Has upon physical examination a rectal deformation or signs of rectal disease such as&#xD;
             fissure, bleeding hemorrhoids, fistula., infection or space occupying lesion.&#xD;
&#xD;
          -  Has received any investigational drug within 90 days of screening;&#xD;
&#xD;
          -  Receipt of any investigational treatment (drug or device) within 90 days prior to&#xD;
             screening;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dept of Gastroeneterology, Asaf Harofe Medical Center</name>
      <address>
        <city>Zrifin</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <study_first_submitted>December 31, 2008</study_first_submitted>
  <study_first_submitted_qc>December 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2009</study_first_posted>
  <last_update_submitted>April 6, 2009</last_update_submitted>
  <last_update_submitted_qc>April 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Michael Shapiro MD</name_title>
    <organization>Gastroenterology Dept, Asaf Harofe Medical Center</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

